Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Mar;71(3):610–613. doi: 10.1038/bjc.1995.118

The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer.

M J Lind 1, L Gumbrell 1, B M Cantwell 1, M J Millward 1, D Simmonds 1, M Proctor 1, F Chapman 1, E McCann 1, I Middleton 1, A H Calvert 1
PMCID: PMC2033646  PMID: 7533518

Abstract

Twenty patients with locally advanced or metastatic breast cancer were treated with four cycles of ifosfamide/mesna 5 g m-2 and epirubicin 60 mg m-2 every 14 days with granulocyte colony-stimulating factor (G-CSF, Filgrastim). Complete remission occurred in six out of the 20 patients (30%, 95% confidence interval 12-54%) and there were 12 partial responders (60%, 95% confidence interval 37-81%), thus giving an overall response rate of 90% (95% confidence interval 63-97%). Two patients had progressive disease. The median duration of response for those patients with metastatic disease was 7.3 (1.3-20.1+) months. The median survival time for these patients was 15 (5.3-27.9+) months. Of the four patients treated with locally advanced disease three achieved a complete clinical response and one a partial response. Three out of four of these patients subsequently underwent a mastectomy, and in one of these no viable tumour was seen. Our conclusion is that this regimen is excellent palliation for metastatic disease and possibly useful neoadjuvant treatment.

Full text

PDF
610

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antman K., Ayash L., Elias A., Wheeler C., Hunt M., Eder J. P., Teicher B. A., Critchlow J., Bibbo J., Schnipper L. E. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol. 1992 Jan;10(1):102–110. doi: 10.1200/JCO.1992.10.1.102. [DOI] [PubMed] [Google Scholar]
  2. Antman K., Gale R. P. Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants. Ann Intern Med. 1988 Apr;108(4):570–574. doi: 10.7326/0003-4819-108-4-570. [DOI] [PubMed] [Google Scholar]
  3. Bronchud M. H., Scarffe J. H., Thatcher N., Crowther D., Souza L. M., Alton N. K., Testa N. G., Dexter T. M. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer. 1987 Dec;56(6):809–813. doi: 10.1038/bjc.1987.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Carmo-Pereira J., Costa F. O., Henriques E., Godinho F., Cantinho-Lopes M. G., Sales-Luis A., Rubens R. D. A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer. 1987 Oct;56(4):471–473. doi: 10.1038/bjc.1987.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Clark G. M., Sledge G. W., Jr, Osborne C. K., McGuire W. L. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987 Jan;5(1):55–61. doi: 10.1200/JCO.1987.5.1.55. [DOI] [PubMed] [Google Scholar]
  6. Dunphy F. R., 2nd, Spitzer G. Long-term complete remission of stage IV breast cancer after high-dose chemotherapy and autologous bone marrow transplantation. Am J Clin Oncol. 1990 Aug;13(4):364–366. doi: 10.1097/00000421-199008000-00017. [DOI] [PubMed] [Google Scholar]
  7. Dunphy F. R., Spitzer G. Use of very-high-dose chemotherapy with autologous bone marrow transplantation in treatment of breast cancer. J Natl Cancer Inst. 1992 Jan 15;84(2):128–129. doi: 10.1093/jnci/84.2.128. [DOI] [PubMed] [Google Scholar]
  8. Eddy D. M. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol. 1992 Apr;10(4):657–670. doi: 10.1200/JCO.1992.10.4.657. [DOI] [PubMed] [Google Scholar]
  9. Eddy D. M., Hillner B. E., Smith T. J., Desch C. E. High-dose chemotherapy with autologous bone marrow transplantation for metastatic breast cancer. JAMA. 1992 Sep 23;268(12):1536–1537. doi: 10.1001/jama.268.12.1536a. [DOI] [PubMed] [Google Scholar]
  10. Fey M. F., Brunner K. W., Sonntag R. W. Prognostic factors in metastatic breast cancer. Cancer Clin Trials. 1981 Fall;4(3):237–247. [PubMed] [Google Scholar]
  11. Hayward J. L., Carbone P. P., Heuson J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977 Mar;39(3):1289–1294. doi: 10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  12. Hoekman K., Wagstaff J., van Groeningen C. J., Vermorken J. B., Boven E., Pinedo H. M. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer. J Natl Cancer Inst. 1991 Nov 6;83(21):1546–1553. doi: 10.1093/jnci/83.21.1546. [DOI] [PubMed] [Google Scholar]
  13. Hortobagyi G. N., Bodey G. P., Buzdar A. U., Frye D., Legha S. S., Malik R., Smith T. L., Blumenschein G. R., Yap H. Y., Rodriguez V. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol. 1987 Mar;5(3):354–364. doi: 10.1200/JCO.1987.5.3.354. [DOI] [PubMed] [Google Scholar]
  14. Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984 Nov;2(11):1281–1288. doi: 10.1200/JCO.1984.2.11.1281. [DOI] [PubMed] [Google Scholar]
  15. Mick R., Begg C. B., Antman K. H., Korzun A. H., Frei E., 3rd Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies? Breast Cancer Res Treat. 1989 Jan;13(1):33–38. doi: 10.1007/BF01806548. [DOI] [PubMed] [Google Scholar]
  16. Millward M. J., Harris A. L., Cantwell B. M. Phase II study of doxorubicin plus ifosfamide/mesna in patients with advanced breast cancer. Cancer. 1990 Jun 1;65(11):2421–2425. doi: 10.1002/1097-0142(19900601)65:11<2421::aid-cncr2820651103>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  17. Paterson A. H., Szafran O., Cornish F., Lees A. W., Hanson J. Effect of chemotherapy on survival in metastatic breast cancer. Breast Cancer Res Treat. 1981;1(4):357–363. doi: 10.1007/BF01806751. [DOI] [PubMed] [Google Scholar]
  18. Scholl S. M., Asselain B., Palangie T., Dorval T., Jouve M., Garcia Giralt E., Vilcoq J., Durand J. C., Pouillart P. Neoadjuvant chemotherapy in operable breast cancer. Eur J Cancer. 1991;27(12):1668–1671. doi: 10.1016/0277-5379(91)90442-g. [DOI] [PubMed] [Google Scholar]
  19. Tannock I. F., Boyd N. F., DeBoer G., Erlichman C., Fine S., Larocque G., Mayers C., Perrault D., Sutherland H. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol. 1988 Sep;6(9):1377–1387. doi: 10.1200/JCO.1988.6.9.1377. [DOI] [PubMed] [Google Scholar]
  20. Tormey D. C., Gelman R., Band P. R., Sears M., Rosenthal S. N., DeWys W., Perlia C., Rice M. A. Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial. Cancer. 1982 Oct 1;50(7):1235–1244. doi: 10.1002/1097-0142(19821001)50:7<1235::aid-cncr2820500703>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  21. Wood W. C., Budman D. R., Korzun A. H., Cooper M. R., Younger J., Hart R. D., Moore A., Ellerton J. A., Norton L., Ferree C. R. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994 May 5;330(18):1253–1259. doi: 10.1056/NEJM199405053301801. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES